These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36203581)

  • 1. Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B.
    Li M; Gao Y; Yang L; Lin Y; Deng W; Jiang T; Bi X; Lu Y; Zhang L; Shen G; Liu R; Wu S; Chang M; Xu M; Hu L; Song R; Jiang Y; Yi W; Xie Y
    Front Immunol; 2022; 13():1024333. PubMed ID: 36203581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Serum IFN- and IL-5 Levels in Response to Entecavir Therapy in Patients with Chronic Hepatitis B Virus Infection.
    Badary TM; ElBadawy O; Agban MN; Kamel S; Sadek A
    Egypt J Immunol; 2018 Jan; 25(1):93-103. PubMed ID: 30243001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on early predictive factors of an incomplete viral response with 48 week-entecavir therapy in HBeAg-positive chronic hepatitis B patients].
    Zhou ZF; Ding Y; Zhang C; Fan YX; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):1008-1012. PubMed ID: 34865347
    [No Abstract]   [Full Text] [Related]  

  • 5. Changes in the Cytokine Profiles of Patients with Chronic Hepatitis B during Antiviral Therapy.
    Li MH; Lu HH; Chen QQ; Lin YJ; Zeng Z; Lu Y; Zhang L; Dong JP; Yi W; Xie Y
    Biomed Environ Sci; 2021 Jun; 34(6):443-453. PubMed ID: 34284852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B.
    He Y; Zhou Y; Wang H; Peng X; Chang Y; Hu P; Ren H; Xu H
    BMC Pediatr; 2022 Jul; 22(1):426. PubMed ID: 35854256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of cytokines with hepatitis B virus and its antigen.
    Li MH; Chen QQ; Zhang L; Lu HH; Sun FF; Zeng Z; Lu Y; Yi W; Xie Y
    J Med Virol; 2020 Dec; 92(12):3426-3435. PubMed ID: 32662892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
    Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association of baseline alanine aminotransferase levels with therapeutic effects of entecavir and interferon-
    Xiao Z; Zhou F; Zhou B; Yang J
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Feb; 39(2):150-155. PubMed ID: 30890501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients.
    Li M; Zhang L; Xie S; Sun F; Zeng Z; Deng W; Jiang T; Bi X; Lin Y; Yang L; Lu Y; Shen G; Liu R; Wu S; Chang M; Hu L; Dong J; Yi W; Xie Y
    Front Immunol; 2022; 13():892031. PubMed ID: 35603222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients.
    Luo H; Zhang XX; Cao LH; Tan N; Kang Q; Xi HL; Yu M; Xu XY
    World J Gastroenterol; 2019 Feb; 25(6):719-728. PubMed ID: 30783375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.
    Xu JH; Fan YN; Yu YY; Si CW; Zeng Z; Xu ZN; Li J; Mao Q; Zhang DZ; Tang H; Sheng JF; Chen XY; Ning Q; Shi GF; Xie Q; Zhang XQ; Dai J
    J Viral Hepat; 2022 Oct; 29(10):862-867. PubMed ID: 35737855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
    Reijnders JG; Rijckborst V; Sonneveld MJ; Scherbeijn SM; Boucher CA; Hansen BE; Janssen HL
    J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
    Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
    [No Abstract]   [Full Text] [Related]  

  • 17. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.
    Huang YJ; Chang CS; Peng YC; Yeh HZ; Yang SS
    PLoS One; 2017; 12(3):e0174046. PubMed ID: 28350873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
    Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL
    Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine Profiles and Virological Marker Monitoring during 48 Weeks Peginterferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B.
    Li MH; Sun FF; Chen FX; Zeng Z; Lin YJ; Bi XY; Yang L; Deng W; Jiang TT; Huang RH; Yi W; Xie Y
    Biomed Environ Sci; 2022 Apr; 35(4):312-321. PubMed ID: 35473895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.